• DOI:10.1586/eem.10.18
• Corpus ID: 73253356

Endocrine treatment of transsexuals: assessment of cardiovascular risk factors

@article{Nakatsuka2010EndocrineTO,
  title={Endocrine treatment of transsexuals: assessment of cardiovascular risk factors},
  author={Mikiya Nakatsuka},
  journal={Expert Review of Endocrinology \& Metabolism},
  year={2010},
  volume={5},
  pages={319 - 322}
}

• M. Nakatsuka
• Published 1 May 2010
• Medicine
• Expert Review of Endocrinology & Metabolism

Gender identity disorder (GID) is characterized by strong and persistent cross-gender identification and by persistent discomfort with one’s anatomical sex. Transsexualism is considered to be the extreme end of the spectrum of GID, which is characterized by a pursuit of sex reassignment surgery. The recent information on the prevalence of the transsexual end of the GID spectrum from The Netherlands is one in 11,900 males and one in 30,400 females [101], although biological mechanisms of GID are still under investigation [1,101]. Transsexuals who require transition to their desired gender must undergo hormonal therapy that masculinize or feminize the body, such as administering testosterone to biologic females or estrogen to biologic males. In many countries, people with GID are treated according to the Standards of Care (SOC) 6th version of the World Professional Association for Transgender Health (WPATH), formerly known as the Harry Benjamin International Gender Dysphoria Association (HBIGDA) a professional organization devoted to the understanding and treatment of gender identity disorders [101]. The Endocrine Society is also formulating practice guidelines for endocrine treatment of transsexual persons [2,3].